Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Via Mariano Semmola, 80131, Naples, Italy.
Clinical Epidemiology Unit, University Hospital "San Martino", Genoa, Italy.
J Transl Med. 2019 May 10;17(1):148. doi: 10.1186/s12967-019-1892-5.
The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.
2018 年黑色素瘤桥接大会（11 月 29 日至 12 月 1 日，意大利那不勒斯）的大辩论环节，专家们就黑色素瘤的三个热门议题展开了针锋相对的观点辩论。这些议题包括：总生存期是否仍应作为黑色素瘤临床试验的主要终点，抗细胞毒性 T 淋巴细胞相关抗原（CTLA）-4 是否仍然是与抗程序性死亡（PD）/PD 配体（L）-1 药物联合使用的最佳药物选择，以及辅助治疗与新辅助治疗在黑色素瘤患者中的地位。本报告总结了这三个重要的辩论。
